QoL · recurrent platinum‐resistant EOC
Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with TKI may leads to higher any adverse events (grade ≥3) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2)Â · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether chemotherapy with TKI changes bowel fistula / perforation (grade ≥ 3) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Progression‐free survival · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes progression‐free survival at 6 months№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
2 findings from 1 review
RR 0.61 [0.22, 1.68]
Studies not reported
Very low
RR 0.65 [0.12, 3.66]
Studies not reported
Very low
Overall survival · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes overall survival compared with treosulfan (very low certainty).
1 finding from 1 review
HR 0.98 [0.58, 1.67]
Studies not reported
Very low
Skin toxicity (alopecia)№ of participants: 73(1 RCT) · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes skin toxicity (alopecia)№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.32 [0.12, 0.91]
Studies not reported
Very low
Nausea and vomiting · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes gastrointestinal toxicity (nausea and vomiting)№ of participants:… compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.65 [0.12, 3.66]
Studies not reported
Very low
Neurotoxicity · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes neurotoxicity№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.32 [0.01, 7.71]
Studies not reported
Very low
Grade 3 to 4 neutropenia · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Overall survival (OS) · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) probably leads to lower overall survival (OS) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).
1 finding from 1 review
Overall response rate (ORR), · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to higher overall response rate (ORR) compared with chemotherapy (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).
1 finding from 1 review
QoL · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to higher QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival (OS) · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) probably leads to lower overall Survival (OS) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate (OSR) · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).
1 finding from 1 review